inclisiran Archives -

Novartis bags elusive US approval for cholesterol drug inclisiran

Phil Taylor Amgen, cholesterol, inclisiran, Leqvio, Novartis, PCSK9, Praluent, Regeneron, regulatory approval, Repatha, Sanofi 0 Comment

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce

Novartis bags elusive US approval for cholesterol drug inclisiran

https://pharmaphorum.com/news/novartis-bags-elusive-us-approval-for-cholesterol-drug-inclisiran/

Market Access/ News/ News

NICE backs NHS use of Novartis’ cholesterol drug Leqvio

Phil Taylor cholesterol, gene silencing, HEOR, inclisiran, Leqvio, market access, NHS, NICE, Novartis, RNAi 0 Comment

Novartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help

NICE backs NHS use of Novartis’ cholesterol drug Leqvio

https://pharmaphorum.com/news/nice-backs-nhs-use-of-novartis-cholesterol-drug-leqvio/

Market Access/ News/ News

Novartis tries to rescue stalled inclisiran filing with FDA

Phil Taylor Alnylam, cardiology, cholesterol, fda, inclisiran, Novartis 0 Comment

Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on

Novartis tries to rescue stalled inclisiran filing with FDA

https://pharmaphorum.com/news/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda/

Market Access/ News/ News

FDA rejects Novartis’ cholesterol drug after factory inspection issue

Richard Staines Alnylam, cardiology, fda, inclisiran, Novartis 0 Comment

Novartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster

FDA rejects Novartis’ cholesterol drug after factory inspection issue

https://pharmaphorum.com/news/fda-rejects-novartis-cholesterol-drug-after-missed-factory-inspection/

Market Access/ News/ News

Novartis’ big bet on inclisiran nears fruition, as CHMP backs drug

Phil Taylor cardiovascular disease, CHMP, cholesterol, ema, inclisiran, Leqvio, Novartis 0 Comment

Novartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering

Novartis’ big bet on inclisiran nears fruition, as CHMP backs drug

https://pharmaphorum.com/news/novartis-big-bet-on-inclisiran-nears-fruition-as-chmp-backs-drug/

News/ News/ R&D

Novartis plots cardio trial in UK as London HQ opens

Richard Staines cardiovascular, clinical trials, inclisiran, market access, NHS, NICE, Novartis, R&D 0 Comment

Novartis has announced the beginnings of a major cardiovascular outcomes trial in the UK, as it opened a

Novartis plots cardio trial in UK as London HQ opens

https://pharmaphorum.com/news/novartis-plots-cardio-trial-in-uk-as-london-hq-opens/

Market Access/ News/ News/ News/ Patients/ Top stories

Novartis strikes landmark deal with NHS to speed up inclisiran access

Phil Taylor cardiovascular disease, cholesterol, inclisiran, NHS England, Novartis 0 Comment

Novartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran

Novartis strikes landmark deal with NHS to speed up inclisiran access

https://pharmaphorum.com/news/novartis-strikes-landmark-deal-with-nhs-to-speed-up-inclisiran-access/

News/ News/ R&D

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?

Phil Taylor Amgen, cardiovascular disease, cholesterol, gene silencing, inclisiran, PCSK9 inhibitors, Praluent, Regeneron, Repatha, RNA interference, Sanofi, The Medicines Company 0 Comment

Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?

https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/

News/ News/ R&D

TMC inches closer to inclisiran approval with long-term safety data

Phil Taylor cholesterol, inclisiran, The Medicines Company, TMC 0 Comment

The Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety

TMC inches closer to inclisiran approval with long-term safety data

https://pharmaphorum.com/news/tmc-inches-closer-to-inclisiran-approval-with-long-term-safety-data/

Trending

inclisiran

Login